Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection.
Melanoma
Tumor draining lymp nodes
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
26
05
2020
accepted:
14
08
2020
pubmed:
21
8
2020
medline:
12
3
2021
entrez:
21
8
2020
Statut:
ppublish
Résumé
In melanoma patients, microscopic tumor in the sentinel lymph-node biopsy (SLN) increases the risk of distant metastases, but the transition from tumor in the SLN to metastatic disease remains poorly understood. Fluorescent staining for CD3, CD20, CD11c, and DNA was performed on SLN tissue and matching primary tumors. Regions of interest (ROI) were then chosen geometrically (e.g., tumor) or by fluorescent cell subset markers (e.g., CD11c). Each ROI was further analyzed using NanoString Digital Spatial Profiling high-resolution multiplex profiling. Digital counts for 59-panel immune-related proteins were collected and normalized to account for system variation and ROI area. Tumor regions of SLNs had variable infiltration of CD3 cells among patients. The patient with overall survival (OS) > 8 years had the most CD11c- and CD3-expressing cells infiltrating the SLN tumor region. All patients had CD11c (dendritic cell, DC) infiltration into the SLN tumor region. Selecting ROI by specific cell subtype, we compared protein expression of CD11c cells between tumor and non-tumor/normal tissue SLN regions. Known markers of DC activation such as CD86, HLA-DR, and OX40L were lowest on CD11c cells within SLN tumor for the patient with OS < 1 year and highest on the patient with OS > 8 years. We demonstrate the feasibility of profiling the protein expression of CD11c cells within the SLN tumor. Identifying early regulators of melanoma control when the disease is microscopically detected in the SLN is beneficial and requires follow-up studies in a larger cohort of patients.
Sections du résumé
BACKGROUND
BACKGROUND
In melanoma patients, microscopic tumor in the sentinel lymph-node biopsy (SLN) increases the risk of distant metastases, but the transition from tumor in the SLN to metastatic disease remains poorly understood.
METHODS
METHODS
Fluorescent staining for CD3, CD20, CD11c, and DNA was performed on SLN tissue and matching primary tumors. Regions of interest (ROI) were then chosen geometrically (e.g., tumor) or by fluorescent cell subset markers (e.g., CD11c). Each ROI was further analyzed using NanoString Digital Spatial Profiling high-resolution multiplex profiling. Digital counts for 59-panel immune-related proteins were collected and normalized to account for system variation and ROI area.
RESULTS
RESULTS
Tumor regions of SLNs had variable infiltration of CD3 cells among patients. The patient with overall survival (OS) > 8 years had the most CD11c- and CD3-expressing cells infiltrating the SLN tumor region. All patients had CD11c (dendritic cell, DC) infiltration into the SLN tumor region. Selecting ROI by specific cell subtype, we compared protein expression of CD11c cells between tumor and non-tumor/normal tissue SLN regions. Known markers of DC activation such as CD86, HLA-DR, and OX40L were lowest on CD11c cells within SLN tumor for the patient with OS < 1 year and highest on the patient with OS > 8 years.
CONCLUSION
CONCLUSIONS
We demonstrate the feasibility of profiling the protein expression of CD11c cells within the SLN tumor. Identifying early regulators of melanoma control when the disease is microscopically detected in the SLN is beneficial and requires follow-up studies in a larger cohort of patients.
Identifiants
pubmed: 32814992
doi: 10.1007/s00262-020-02698-2
pii: 10.1007/s00262-020-02698-2
pmc: PMC7892641
mid: NIHMS1622011
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
475-483Subventions
Organisme : School of Medicine, Duke University
ID : OPSD
Organisme : Society of Surgical Oncology
ID : SSO YIA 2019
Organisme : NCI NIH HHS
ID : K08 CA237726
Pays : United States
Organisme : NIH HHS
ID : T32-CA093245
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA093245
Pays : United States
Organisme : NIH HHS
ID : K08 CA237726-01A1
Pays : United States
Références
Methods Mol Biol. 2020;2055:563-583
pubmed: 31502169
J Am Acad Dermatol. 2017 Feb;76(2):258-263
pubmed: 27887797
Cancer Immunol Res. 2015 Sep;3(9):1082-95
pubmed: 26041736
Lancet Oncol. 2019 Aug;20(8):1083-1097
pubmed: 31221619
PLoS One. 2015 Jul 28;10(7):e0133363
pubmed: 26218530
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Nat Med. 2018 Nov;24(11):1655-1661
pubmed: 30297911
Melanoma Res. 2017 Dec;27(6):565-572
pubmed: 28984690
J Invest Dermatol. 2018 Mar;138(3):679-687
pubmed: 29054599
Science. 2002 Sep 13;297(5588):1867-70
pubmed: 12228717
J Invest Dermatol. 2015 Apr;135(4):1190-1193
pubmed: 25330295
Cancer Res. 2004 Mar 15;64(6):2192-8
pubmed: 15026362
Melanoma Res. 2017 Oct;27(5):429-438
pubmed: 28825947
Eur J Cancer. 2018 Jun;96:25-33
pubmed: 29660597
Clin Cancer Res. 2019 Sep 15;25(18):5503-5512
pubmed: 31189645
Nat Med. 2018 Nov;24(11):1649-1654
pubmed: 30297909
Cancer Immunol Res. 2018 Jan;6(1):14-24
pubmed: 29097422
Lancet Oncol. 2018 Dec;19(12):e720-e725
pubmed: 30507438
N Engl J Med. 2014 Feb 13;370(7):599-609
pubmed: 24521106
Mod Pathol. 2012 Jul;25(7):1000-10
pubmed: 22425909
Br J Dermatol. 2014 Nov;171(5):987-95
pubmed: 24814041